Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Pharmacol Ther. 2007 May;81(5):756-60. Epub 2007 Mar 28.

Obesity pharmacotherapy from a regulatory perspective: overview and key challenges.

Author information

  • 1Pfizer Global Research and Development, New London, Connecticut, USA. Nancy.Hutchinson@pfizer.com

Abstract

Obesity is an epidemic with tremendous impact on both patients and health-care systems globally. This paper explores some of the questions related to the clinical development of new pharmacotherapies in the context of an evolving regulatory perspective. These include patient entry criteria, clinical database size, study designs, weight loss end points (including those for maintenance of weight loss and prevention of weight regain), clinically important patient-reported outcomes, comorbidity/risk factor end points, and challenges in establishing safety and efficacy in adolescent/pediatric patients, and approaches to the development of combination pharmacotherapies. Ultimately, patients, physicians, academia, industry, payers, and governments must continue to partner with regulators to help establish the appropriate balance between the known adverse consequences associated with inadequate treatment of the growing obesity epidemic and the concern for potential unknown risks that may be associated with the long-term use of new pharmacotherapies.

PMID:
17392723
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk